Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese

Momoko Oe1,2, Kazuya Fujihara1*, Mayuko Harada-Yamada1, Taeko Osawa1, Masaru Kitazawa1, Yasuhiro Matsubayashi1, Takaaki Sato1, Yuta Yaguchi1, Midori Iwanaga1, Hiroyasu Seida3, Takaho Yamada1 and Hirohito Sone1

Abstract

Background: Although both a history of cerebrovascular disease (CVD) and glucose abnormality are risk factors for CVD, few large studies have examined their association with subsequent CVD in the same cohort. Thus, we compared the impact of prior CVD, glucose status, and their combinations on subsequent CVD using real-world data.

Methods: This is a retrospective cohort study including 363,627 men aged 18–72 years followed for ≥3 years between 2008 and 2016. Participants were classified as normoglycemia, borderline glycemia, or diabetes defined by fasting plasma glucose, HbA1c, and antidiabetic drug prescription. Prior and subsequent CVD (i.e. ischemic stroke, transient ischemic attack, and non-traumatic intracerebral hemorrhage) were identified according to claims using ICD-10 codes, medical procedures, and questionnaires.

Results: Participants’ mean age was 46.1 ± 9.3, and median follow up was 5.2 (4.2, 6.7) years. Cox regression analysis showed that prior CVD + conferred excess risk for CVD regardless of glucose status (normoglycemia: hazard ratio (HR), 8.77; 95% CI 6.96–11.05; borderline glycemia: HR, 7.40, 95% CI 5.97–9.17; diabetes: HR, 5.73, 95% CI 4.52–7.25). Compared with normoglycemia, borderline glycemia did not influence risk of CVD, whereas diabetes affected subsequent CVD in those with CVD- (HR, 1.50, 95% CI 1.34–1.68). In CVD-/diabetes, age, current smoking, systolic blood pressure, high-density lipoprotein cholesterol, and HbA1c were associated with risk of CVD, but only systolic blood pressure was related to CVD risk in CVD+/diabetes.

Conclusions: Prior CVD had a greater impact on the risk of CVD than glucose tolerance and glycemic control. In participants with diabetes and prior CVD, systolic blood pressure was a stronger risk factor than HbA1c. Individualized treatment strategies should consider glucose tolerance status and prior CVD.

Keywords: Diabetes mellitus, Borderline glycemia, Epidemiology, Cerebrovascular disease

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Japan [2], stroke has many serious sequelae such as paralysis and dysarthria [3]. In addition, mean cost of post-stroke care per patient month was $1,515, which imposes a considerable economic burden [4]. Therefore, to identify patients at high risk for CVD is relevant and urgent with regard to a healthy life expectancy and the economic burden.

A history of CVD greatly increases the risk of subsequent CVD. A meta-analysis showed a recurrence rate of stroke of 3.1% at 30 days, 11.1% at 1 year, and 39.2% at 10 years after the first onset [5]. In Japan, the cumulative recurrence rates were reported to be 35.3% at 5 years and 51.3% at 10 years for stroke of all etiologies [6], and 3.81% at 1 year for ischemic stroke [7].

Diabetes as well as blood pressure is a well-established modifiable risk factor for CVD [8, 9]. A meta-analysis reported that diabetes increased the risk of ischemic stroke by approximately twofold and the risk of hemorrhagic stroke by 1.5-fold in primary prevention [10] and by 1.45-fold for secondary prevention [11]. On the other hand, there is a lack of consensus on the impact of borderline glycemia on the development of stroke [12–14].

Although diabetes mellitus was considered to be as great a risk for coronary artery disease (CAD) as a history of CAD [15], we showed that borderline glycemia had only a slight impact on CAD regardless of a history of CAD. A history of CAD increased the risk of future CAD 5–8 times whereas diabetes increased the risk of future CAD only about 2 times in Japanese men [16]. In our study, the impact of prior CAD and glucose status was evaluated in detail with a clear distinction between borderline glycemia and diabetes. However, few large studies have examined the impact of a history of CVD and glucose status on subsequent CVD development [17–19]. Therefore, we investigated the impact of glucose status and a history of CVD on subsequent CVD in Japanese men using real-world data.

Methods
The present study retrospectively analyzed data from a nationwide claims-based database that included information on 805,992 people enrolled with a health insurance provider for company employees and their dependents in Japan. Details of the claims data and classifications were described elsewhere [20, 21]. Men aged 18–72 years who had been followed for at least 3 years between 1 April 2008 and 31 July 2016 were included and followed up to 31 August 2019. Excluded were women (n = 297,868) because of their lower incidence of CVD, individuals who were not followed at least 3 years, and those with no health examination data including blood test results (n = 144,497). Finally, data were analyzed on 363,627 men.

Participants were classified as having normoglycemia, borderline glycemia, or diabetes mellitus (DM) defined by fasting plasma glucose (FPG), HbA1c, and claims database data as follows: normoglycemia, both FPG < 5.6 mmol/L and HbA1c < 5.7% (39 mmol/mol) and no antidiabetic drug prescription; borderline glycemia, either FPG 5.6–6.9 mmol/L or HbA1c 5.7–6.4% (39–46 mmol/mol) or both and no antidiabetic drug prescription; and DM, FPG ≥ 7.0 mmol/L or HbA1c ≥ 6.5% (47 mmol/mol) or both or with an antidiabetic drug prescription regardless of FPG or HbA1c. Participants who had prior CVD at baseline and subsequent fatal or non-fatal CVD events, such as ischemic stroke, transient ischemic attack, and non-traumatic intracerebral hemorrhage, were identified according to claims using International Classification of Disease 10th revision (ICD-10) codes for CVD and medical procedures and questionnaires [22].

Categorical variables were expressed as numerals and percentages and were compared with χ² tests. Continuous variables were expressed as mean ± SD or median and interquartile range. Continuous variables were compared using the unpaired Student’s t-test or Mann–Whitney U-test for two group comparisons based on their distributions. Multivariate Cox regression hazard model identified variables related to the incidence of CVD. Covariates included factors with few missing data and were not affected by blood collection time, such as age, body mass index (BMI), systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and current smoking, in analyses of the impact of prior CVD and glucose status and their combination. We calculated the hazard ratio (HR) per 1-SD increment for several variables to directly compare the effect of traditional risk factors. Analyses were performed using SPSS (version 19.0, IBM, Chicago, IL, USA). Statistical significance was considered for P < 0.05. The Ethics Committee of Niigata University approved this study.

Results
Baseline characteristics of our study participants according to glucose status and prior CVD are shown in Table 1. The median follow-up period was 5.2 (4.2, 6.7) years.

Among 363,627 participants, 210,434, 119,933, and 33,260 had normoglycemia, borderline glycemia, and DM, respectively. Of those with normoglycemia, borderline glycemia, and DM, 1314, 1240, and 834, respectively, had prior CVD (CVD +). During the study period, 1,025, 961, and 556 CVD events occurred in CVD- and 82, 98, and 85 CVD events occurred in CVD+, respectively, in participants with normoglycemia, borderline glycemia, and DM. The incidences of CVD in CVD- and
### Table 1  Baseline characteristics of study participants according to glucose status and prior cerebrovascular diseases

| Characteristics | Normoglycemia | P-value | Border | P-value | Diabetes | P-value |
|-----------------|---------------|---------|--------|---------|----------|---------|
|                 | Prior CVD(-)  | Prior CVD(+) |          | Prior CVD(-)  | Prior CVD(+) |          | Prior CVD(-)  | Prior CVD(+) |
|                 | n = 209,120   | n = 1314 |        | n = 118,693 | n = 1240 |        | n = 32,426 | n = 834 |
| Age (y)         | 43.6 ± 9.1    |          | < 0.001 | 48.6 ± 8.5    |          | < 0.001 | 51.9 ± 8.1 |          | < 0.001 |
| BMI (kg/m²)     | 23.0 ± 3.0    |          | < 0.001 | 24.2 ± 3.4    |          | < 0.001 | 26.2 ± 4.3 |          | 0.810   |
| SBP (mmHg)      | 119.8 ± 13.9  |          | < 0.001 | 124.1 ± 15.1  |          | < 0.001 | 129.9 ± 16.4 |          | 0.034   |
| DBP (mmHg)      | 74.8 ± 10.8   |          | < 0.001 | 78.4 ± 11.1   |          | < 0.001 | 80.9 ± 11.1 |          | 0.040   |
| HbA1c (mmol/mol) | 34.1 ± 2.5    |          | < 0.001 | 38.4 ± 3.4    |          | < 0.001 | 54.3 ± 14.9 |          | < 0.001 |
| FPG (mmol/L)    | 4.95 ± 0.35   |          | < 0.001 | 5.64 ± 0.50   |          | < 0.001 | 7.9 ± 2.2   |          | 0.005   |
| LDL cholesterol (mmol/L) | 3.12 ± 0.78 |          | < 0.001 | 3.32 ± 0.80   |          | < 0.001 | 3.20 ± 0.84 |          | < 0.001 |
| HDL cholesterol (mmol/L) | 1.53 ± 0.38 |          |         | 1.52 ± 0.37   | 0.829 | < 0.001 | 1.48 ± 0.38 |          | < 0.001 |
| Triglycerides (mmol/L) | 1.04 (0.73–1.51) | 1.08 (0.78–1.55) | 0.006 | 1.25 (0.87–1.83) | 1.30 (0.93–1.83) | < 0.001 | 1.47 (1.02–2.19) | 1.35 (0.96–2.01) | < 0.001 |
| Current smoking (%) | 78,552 (37.6) | 264 (20.1) | 0.006 | 44,319 (37.3) | 267 (21.5) | < 0.001 | 13,227 (40.8) | 207 (24.8) | < 0.001 |
| History of hypertension (%) | 30,960 (14.8) | 574 (43.7) | < 0.001 | 32,190 (27.1) | 734 (59.2) | < 0.001 | 16,057 (49.5) | 632 (75.8) | < 0.001 |
| History of dyslipidemia (%) | 87,095 (41.6) | 711 (54.1) | < 0.001 | 67,540 (56.9) | 824 (66.5) | < 0.001 | 23,302 (71.9) | 671 (80.5) | < 0.001 |
| Medications | β-blockers (%) | 1391 (0.7) | 66 (5.0) | < 0.001 | 2068 (1.7) | 95 (7.7) | < 0.001 | 1576 (4.9) | 127 (15.2) | < 0.001 |
| ACEs and ARBs (%) | 3.7750 (3.7) | 353 (26.9) | < 0.001 | 9709 (8.2) | 449 (36.2) | < 0.001 | 8054 (24.8) | 448 (33.7) | < 0.001 |
| CCBs (%) | 7318 (3.5) | 312 (23.7) | < 0.001 | 9715 (8.2) | 421 (34.0) | < 0.001 | 6728 (20.7) | 378 (45.3) | < 0.001 |
| Diuretics (%) | 1260 (0.6) | 46 (3.5) | < 0.001 | 1774 (1.5) | 97 (7.8) | < 0.001 | 1501 (4.6) | 92 (11.0) | < 0.001 |
| Statins (%) | 5014 (2.4) | 232 (17.7) | < 0.001 | 7212 (6.1) | 326 (26.3) | < 0.001 | 7050 (21.7) | 381 (45.7) | < 0.001 |
| Antiplatelet agents (%) | 879 (0.4) | 327 (24.9) | < 0.001 | 1177 (1.0) | 405 (32.7) | < 0.001 | 1508 (4.7) | 425 (51.0) | < 0.001 |
| OHAs (%) | 383 (%) | 13,566 (41.8) | 491 (58.9) | < 0.001 | 105 (0.3) | 8 (1.0) | 0.002 | 989 (3.1) | 44 (3.3) | < 0.001 |

Data are presented as mean ± SD or median (interquartile range), n (%). International Federation of Clinical Chemistry and Laboratory Medicine units

ACEs angiotensin-converting enzyme inhibitors, ARBs angiotensin-receptor blockers, BMI body mass index, Border borderline glycemia, CCBs calcium-channel blockers, CVD cerebrovascular disease, DBP diastolic blood pressure, FPG fasting plasma glucose, GLP-1 glucagon-like peptide 1 receptor agonists, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, OHAs oral hypoglycemic agents, SBP systolic blood pressure

Hypertension was defined as SBP > 140 mmHg, DBP > 90 mmHg, or treatment for hypertension

Dyslipidemia was defined as LDL cholesterol > 3.6 mmol/L, HDL cholesterol < 1.0 mmol/L, triglycerides > 1.6 mmol/L, or treatment for dyslipidemia

CVD+ participants were 0.88 and 12.69 in those with normoglycemia, 1.46 and 16.43 in participants with borderline glycemia, and 3.11 and 21.44 in those with diabetes per 1,000 person-years, respectively.

As shown in Table 1, smoking rate and LDL-C were lower in the CVD+ groups than in the CVD- groups. SBP, HbA1c, FPG, and triglycerides (TG) were lower in CVD- than in CVD+ in those with normal glycemia and borderline glycemia, whereas HbA1c, FPG, and TG were well controlled in CVD+ among DM participants. Percentages of persons with a history of hypertension and dyslipidemia and users of medication for hypertension and dyslipidemia were significantly higher in CVD+. In those with a DM status, more participants used antidiabetic agents in the CAD+ than in the CAD- group.

In CVD- groups, SBP, diastolic blood pressure (DBP), HbA1c, FPG, TG, and current smoking rate tended to be high, and there was no difference in LDL-C between those with and without new CVD events during the follow-up period in each glucose category. In contrast, among CVD+, the state of control of traditional risk factors at baseline except for SBP was similar among those with or without subsequent CVD events in the borderline glycemia and DM categories (see Additional file 1: Table S1).
Table 2  Relationship of prior cerebrovascular disease and glucose status to incident cerebrovascular disease

|                | Normoglycemia | P-value | Borderline glyemia | P-value | Diabetes | P-value |
|----------------|---------------|---------|--------------------|---------|----------|---------|
|                | Hazard ratio (95% CI) |         | Hazard ratio (95% CI) |         | Hazard ratio (95% CI) |         |
| Prior CVD-     | 1 [Reference] |         | 1 [Reference] |         | 1 [Reference] |         |
| Prior CVD+     | 0.65 (0.58–0.72) | < 0.001 | 0.70 (0.63–0.78) | < 0.001 | 1 [Reference] |         |
| Prior CVD-     | 5.83 (4.61–7.37) | < 0.001 | 5.20 (4.19–6.46) | < 0.001 | 5.41 (4.30–6.81) | < 0.001 |
| Prior CVD+     | 9.03 (7.20–11.34) | < 0.001 | 8.06 (6.52–9.98) | < 0.001 | 8.39 (6.67–10.56) | < 0.001 |
| Prior CVD-     | 1.06 (0.97–1.16) | < 0.001 | 1.50 (1.34–1.68) | < 0.001 | 1.55 (1.39–1.74) | < 0.001 |
| Prior CVD+     | 1.13 (0.83–1.53) | 0.433   | 1.32 (0.94–1.84) | 0.110   |          |         |

Each variable for CVD was adjusted for age, body mass index, systolic blood pressure, LDL cholesterol, HDL cholesterol, and current smoking.

Fig. 1  Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease. Multivariate Cox analysis of the relationship of prior CVD and glucose status to incident CVD. A Impact of prior CVD on subsequent CVD according to glucose status. *P < 0.001 vs. without prior CVD. B Impact of glucose status on subsequent CVD in patients without prior CVD. *P < 0.001 vs. NGT. C Impact of glucose status on subsequent CVD in patients with prior CVD. *P < 0.001 vs. NGT. D Impact of prior CVD and glucose status on subsequent CVD. *P < 0.001 vs. NGT without prior CVD. E Impact of prior CVD and glucose status on subsequent CVD. *P < 0.001 vs. Diabetes without prior CVD. Each variable for CVD was adjusted for age, current smoking, body mass index, systolic blood pressure, LDL-C and HDL-C. Bars indicate 95% confidence intervals. Details are in Table 2. Border, borderline glycemia; CVD, cerebrovascular disease; NGT, normoglycemia.
Table 2 and Fig. 1 show the multivariate-adjusted HRs for subsequent CVD events according to glucose status and prior CVD status. Compared with the CVD- groups, CVD+ groups had approximately five to eightfold increases in subsequent CVD events regardless of glucose status (rows 1 and 2 from the top of Table 2 and Fig. 1A). As shown in rows 3 and 4 of Table 2 and Fig. 1B, C, the presence of borderline glycemia had no influence on future CVD events independently of prior CVD status. DM affected the incidence of CVD events only in the CVD- group. No additive effect of prior CVD and DM was observed.

Table 3 and Fig. 2 show the HRs of each variable on for future CVD according to prior CVD and glucose status. In the CVD- groups, age, current smoking, SBP, and HDL-C were associated with the risk of incident CVD. On the other hand, in the CVD+ groups, SBP was the only factor related to the risk of CVD in the presence of borderline glycemia or DM. The impact of a 1 SD increase in SBP was greater in those with normoglycemia than DM, whereas HbA1c was a significant risk factor only in the CVD-/DM group. In the CVD+/normoglycemia group, no traditional risk factor was related to subsequent CVD events. LDL-C was not a risk factor in any category according to either glycemia status or prior CVD.

Discussion
Main findings
The present study is the first to examine the impact of prior CVD and glucose status on subsequent CVD in a single large population. A history of CVD conferred a five to eightfold increase in subsequent CVD. Diabetes increased the risk of subsequent CVD in participants without a history of CVD whereas borderline glycemia was not related to the risk of subsequent CVD in such participants. On the other hand, neither borderline glycemia nor diabetes increased the risk of subsequent CVD in those with CVD+ (Table 2). These results suggest that the impact of glucose status on CVD is small compared to a history of CVD.

Impact of glucose status on CVD
In our previous study, the combination of CAD+ and diabetes had an additive impact on the development of a new CAD event [16]. The impact of a history of CAD on subsequent CAD was stronger than that of DM, but not as strong as the impact of prior CVD on the development of a new CVD event. Huang et al. reported that elevated HbA1c was associated with an increased risk of coronary heart disease but not with that of stroke in patients with atherosclerotic cardiovascular disease [14]. Those findings are consistent with findings of our previous study on CAD [16] and the current study on CVD, suggesting that the impact of glucose metabolism abnormalities on CVD was modest compared with that of CAD.

Impact of SBP on CVD
In our current study, the effect of blood pressure was much greater on CVD than that of glucose abnormality. In fact, HbA1c was a risk factor in CVD-/DM but not CVD+/DM in an analysis of traditional risk factors (Table 3). SBP was more strongly associated with CVD risk than glycemia in DM with prior CVD. These results indicate that in devising individualized treatment strategies both glucose tolerance status and prior CVD should be considered.

In those with CVD+, SBP was associated with the risk of CVD in the borderline glycemia and diabetes groups but not in the normoglycemia group (Table 3). A previous meta-analysis reported that the optimal SBP for cardiovascular disease prevention was less than 130 mmHg [24, 25]. Our results showed that the mean baseline SBP was 123.1 ± 14.0 mmHg in the normoglycemia group, 127.1 ± 15.0 mmHg in the borderline glycemia group, and 131.1 ± 15.8 mmHg in the diabetes group, which was lowest in the normoglycemia group. When baseline SBP was compared according to the presence or absence of CVD during the follow-up period, occurrence of CVD was significantly higher in those with borderline glycemia and diabetes but not normoglycemia (Supplementary Table). Thus, blood pressure in people with a history of CVD may be well controlled in the absence of abnormal glucose metabolism. The need for stringent antihypertensive treatment was shown by the United Kingdom Prospective Diabetes Study (UKPDS) 38 and the Hypertension Optimal Treatment (HOT) study [26, 27]. In the present study, although the prescription rate for antihypertensive drugs tended to be highest in DM followed by borderline glycemia and normoglycemia in those with a history of CVD, the mean SBP was higher with worsening of the glucose status. On the other hand, the rate of prescriptions for statins tended to be higher and mean LDL-C values tended to be lower with worsening of the glucose status or with a history of CVD. Histories of stroke, diabetes or their combination are important risk factors for atherosclerotic disease, and strict control of LDL-C in these patients has been recommended in guidelines [28–30]. The significance of comprehensive risk management in diabetes was demonstrated in the Steno-2 study [31, 32] and partially in J-DOIT3 [33]. The present results may reflect the situation whereby LDL-C management is generally successful but that of blood...
Table 3  Impact of risk factors for cerebrovascular disease according to prior cerebrovascular disease and glucose status

| Prior CVD (-) | Normoglycemia | Border | Diabetes | Prior CVD (+) | Normoglycemia | Border | Diabetes |
|---------------|----------------|--------|----------|---------------|----------------|--------|----------|
| Age (per/y increase) | 1.08 (1.07–1.09) | <0.001 | 1.08 (1.07–1.09) | <0.001 | 1.06 (1.05–1.08) | <0.001 | 1.02 (0.99–1.05) | 0.122 | 1.03 (1.00–1.06) | 0.025 | 1.03 (0.99–1.06) | 0.125 |
| Current smoking (yes/no) | 1.48 (1.31–1.68) | <0.001 | 1.54 (1.35–1.75) | <0.001 | 1.54 (1.29–1.82) | <0.001 | 1.23 (0.73–2.08) | 0.436 | 0.98 (0.60–1.59) | 0.927 | 1.32 (0.81–2.16) | 0.261 |
| BMI | | | | | | | | | | | |
| Per 5 kg/m² increase | 1.10 (0.98–1.23) | 0.093 | 1.09 (0.98–1.21) | 0.109 | 0.95 (0.84–1.06) | 0.335 | 1.02 (0.69–1.52) | 0.914 | 0.92 (0.66–1.28) | 0.604 | 1.03 (0.78–1.37) | 0.819 |
| Per 1 SD increase | 1.07 (0.99–1.15) | 1.06 (0.99–1.14) | 0.96 (0.89–1.04) | 1.02 (0.77–1.33) | 0.94 (0.75–1.18) | 1.02 (0.85–1.24) |
| Systolic blood pressure | | | | | | | | | | | |
| Per 10 mmHg increase | 1.36 (1.31–1.41) | <0.001 | 1.32 (1.27–1.37) | <0.001 | 1.23 (1.18–1.29) | <0.001 | 1.00 (0.85–1.18) | 0.965 | 1.18 (1.04–1.34) | 0.012 | 1.27 (1.12–1.44) | <0.001 |
| Per 1 SD increase | 1.58 (1.50–1.68) | 1.51 (1.43–1.59) | 1.37 (1.28–1.46) | 1.01 (0.79–1.28) | 1.27 (1.05–1.54) | 1.43 (1.19–1.72) |
| LDL cholesterol | | | | | | | | | | | |
| Per 1 mmol/L increase | 0.98 (0.90–1.06) | 0.606 | 0.97 (0.90–1.06) | 0.511 | 0.95 (0.86–1.05) | 0.333 | 0.78 (0.58–1.05) | 0.096 | 0.93 (0.72–1.21) | 0.600 | 0.95 (0.74–1.21) | 0.664 |
| Per 1 SD increase | 0.98 (0.92–1.05) | 0.98 (0.92–1.04) | 0.96 (0.89–1.04) | 0.82 (0.65–1.04) | 0.95 (0.77–1.16) | 0.96 (0.79–1.17) |
| HDL cholesterol | | | | | | | | | | | |
| Per 1 mmol/L increase | 0.82 (0.69–0.98) | 0.028 | 0.79 (0.66–0.95) | 0.013 | 0.68 (0.52–0.88) | 0.003 | 0.94 (0.51–1.74) | 0.843 | 0.70 (0.39–1.28) | 0.245 | 1.48 (0.79–2.76) | 0.224 |
| Per 1 SD increase | 0.93 (0.87–0.99) | 0.91 (0.85–0.98) | 0.86 (0.78–0.95) | 0.98 (0.77–1.24) | 0.87 (0.70–1.10) | 1.16 (0.91–1.47) |
| HbA1c | | | | | | | | | | | |
| Per 1 mmol/L increase | 0.98 (0.96–1.01) | 0.190 | 1.02 (1.00–1.04) | 0.090 | 1.01 (1.01–1.02) | <0.001 | 0.96 (0.88–1.04) | 0.327 | 1.02 (0.96–1.09) | 0.477 | 1.01 (0.99–1.02) | 0.359 |
| Per 1 SD increase | 0.88 (0.73–1.06) | 1.14 (0.98–1.32) | 1.08 (1.04–1.13) | 0.71 (0.64–1.40) | 1.18 (0.74–1.88) | 1.06 (0.94–1.19) |

Each variable for CVD adjusted for age, current smoking, BMI, systolic blood pressure, LDL cholesterol, HDL cholesterol, and HbA1c. Border, borderline glycemia; CVD, cerebrovascular disease; HR, hazard ratio; P, p-value; SD, standard deviation
pressure remains an issue especially in patients with abnormal glucose metabolism in Japan. Recently, galectin-3 has been attracting attention as a novel therapeutic target [34]. It has the potential to influence future therapeutic strategies as well as blood pressure control.

Impact of weight loss on CVD

Weight loss is a key factor in the prevention of cardiovascular disease. The Diabetes Prevention Program Outcomes Study showed that a lifestyle intervention involving weight loss reduced the incidence of DM [35]. UKPDS showed a modest effect of glycemic control on cardiovascular disease suppression [36] and that the suppression of cardiovascular events by metformin in overweight type 2 diabetic patients is independent of blood glucose values [37]. In the Look AHEAD trial, although weight loss did not reduce the incidence of cardiovascular disease, weight loss was associated with improvement of various risk factors for cardiovascular disease [38]. Similar results were observed in interventional trials in Japan [39, 40]. Unfortunately, our database did not include data on body weight changes. High triglyceride-glucose index levels were associated with subclinical cerebral small vessel disease in a neurologically healthy population [41] and elevated levels of adiponectin were associated with major adverse cardiovascular and cerebrovascular events and mortality risk in patients with ischemic CVD [42]. Thus, future study is needed to clarify the impact of prior CVD and glucose status on incident CVD considering these important factors.

Strengths and limitations

The strength of our study was the combination of information on health examinations and from a claims database to assess glucose status based on clinical laboratory values and drug prescriptions and identification of CVD based on ICD-10 codes and procedures. Therefore, we were able to estimate the risk of CVD in a real-world setting on a large scale. Also of significance was that our study mainly examined the working
generation, which has the greatest impact on economic activity. In addition, only cases with a long-term follow-up of at least three years were evaluated.

However, our study has some limitations. First, we excluded women because of the lower incidence of CVD. Although it was reported that the impact of impaired glucose tolerance on CVD may differ between men and women [43, 44], sex differences in incident stroke are greater in East Asia than in Western regions [45]. Thus, a larger cohort is needed to obtain a sufficient number of stroke events in East Asian women for a meaningful analysis. Second, since we do not have data from oral glucose tolerance tests (OGTTs), it is possible that the normoglycemia group included cases with impaired glucose tolerance. Previous studies showed that the impact of glucose abnormality on CVD was different between cases evaluated by fasting blood glucose and those evaluated by OGTT 2-h values [46, 47]. Although the OGTT is not always routinely performed in health check-ups and clinical settings, it is desirable to construct data that include the results of OGTTs. Third, we did not examine each subtype of CVD. Although Asians and non-Asians have the same risks of cardiovascular death, non-fatal stroke and non-fatal acute coronary syndrome, the risk of intracranial hemorrhage is 2.2 times higher in Asians [48]. In addition, diabetes has been reported to be associated with the risk of ischemic stroke and lacunar infarction, but not with other strokes [49, 50]. Therefore, a further stratified analysis is needed with regard to the subtypes of CVD. Finally, the impact of changes in glucose abnormality status, other risk factors, and treatment during follow-up could not be examined. It was reported that the transition from borderline glycemia to diabetes increases the risk of cardiovascular disease [51]. To accurately examine the risk of borderline glycemia, it would be necessary to determine whether the status of borderline glycemia persisted or progressed to diabetes during the follow-up.

Conclusion
A history of CVD greatly increased the risk of subsequent CVD regardless of glucose status. Diabetes increased the risk of CVD in primary prevention, but less in secondary prevention. Individualized treatment strategies are needed in consideration of risk factors, such as glucose tolerance status and prior CVD.

Abbreviations
BMI: Body mass index; CAD: Coronary artery disease; CVD: Cerebrovascular disease; DBP: Diastolic blood pressure; DM: Diabetes mellitus; FPG: Fasting plasma glucose; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; SBP: Systolic blood pressure; TG: Triglycerides.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-021-01367-7.

Additional file 1: Table S1. Characteristics of study participants with or without subsequent cerebrovascular diseases during the observation period according to prior cerebrovascular disease and glucose status

Acknowledgements
The authors thank Ms. M. H., Niigata University Faculty of Medicine, for excellent secretarial assistance.

Authors’ contributions
MO developed the study design, researched the data, contributed to discussions, wrote the manuscript, and reviewed and edited the manuscript. KF planned and supervised this research, researched the data, contributed to discussions, wrote the manuscript, and reviewed and edited the manuscript. MHY, TO, MK, YM, TS, YY, MI, HS and TY researched the data, contributed to discussions, wrote the manuscript and reviewed and edited the manuscript. HS developed the study design, contributed to discussions, and reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding
This work is supported by JMDC Inc., the Japan Society for Promotion of Science (JSPS), and the Ministry of Health, Labour and Welfare. The sponsor had no role in the design and conduct of the study.

Availability of data and materials
The data that support the findings of this study are available from JMDC Inc. but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission from JMDC Inc.

Declarations
Ethics approval and consent to participate
The Ethics Committee of Niigata University approved this study.

Consent for publication
Not applicable.

Competing interests
M.O. is employees of Kowa Co., Ltd. No other conflicts of interest relevant to this article exist.

Author details
1 Department of Internal Medicine, Niigata University Faculty of Medicine, 1-754 Asahimachi, Niigata, Niigata 951‑8510, Japan. 2 Kowa Company. Ltd, 10‑4 Nihonbashi‑honcho 3‑chome, Chuo‑ku, Tokyo 103‑0023, Japan. 3 JMDC Inc, 2‑5‑5 Shiba Daimon, Minato‑ku, Tokyo 105‑0012, Japan.

Received: 28 June 2021 Accepted: 20 August 2021
Published online: 03 September 2021

References
1. GBD 2016 Stroke Collaborators: Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, Abd Allah F, Abdelalim AF, Abraha HN, Abu‑Rmeileh NM, et al. Global, regional, and national burden of stroke, 1990—2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5): 439–458.
2. Director-General for statistics, Information Policy and Policy Evaluation, The Ministry of Health, Labour and Welfare. The Vital Statistics of Japan 2018. https://www.mhlw.go.jp/english/database/db‑hw/dl/81‑1a2en.pdf.
3. Jørgensen HS, Nakayama H, Raaschou HO, Vive-Larsen J, Staer M, Olsen TS. Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995;76(6):399–405.

4. Rajic S, Golhe H, Borba HH, Szczytnik G, Vujicic J, Toelt J, Siebert U. Economic burden of stroke: a systematic review on post-stroke care. Eur J Health Econ. 2019;20(1):107–34.

5. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL. Grieve AP Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489–94.

6. Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, Oishi Y, Imai H, et al. Ten-year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2005;76(3):368–72.

7. Suzuki N, Sato M, Houskin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Origasa H, et al. One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event Reduction after Stroke) registry. J Stroke Cerebrovasc Dis. 2012;21(4):245–53.

8. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Cockroft KM, Gutierrez J, Lombrano M, Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, Oishi Y, Imai H, et al. Ten-year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2015;86(7):776–82.

9. Jaspers SH, Nakayama H, Raaschou HO, Vive-Larsen J, Staer M, Olsen TS. Outcome and time course of recovery in stroke. Part II: Course. The Copenhagen Stroke Study. Arch Phys Med Rehabil. 1995;76(6):399–405.

10. Rajic S, Golhe H, Borba HH, Szczytnik G, Vujicic J, Toelt J, Siebert U. Economic burden of stroke: a systematic review on post-stroke care. Eur J Health Econ. 2019;20(1):107–34.

11. Chen J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for cardiovascular disease in subjects with type 2 diabetes and in nondiabetic subjects. Metabolism. 2019;101:153991.

12. Chen J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for cardiovascular disease in subjects with type 2 diabetes and in nondiabetic subjects. Metabolism. 2019;101:153991.

13. Mitsios JP, Ekinci EI, Mitsios GP, Churilov L, Thijs V. Relationship between HbA1c and cardiovascular events in patients with type 2 diabetes. Diabetes Metab. 2017;43(3):261–4.

14. Fujihara K, Yamada-Harada M, Matsubayashi Y, Matsuoka Y, Kato K, Tsuchiya K, Maeda H, Nakamura H, Oishi Y, Imai H, et al. Ten-year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2005;76(3):368–712.

15. Suzukia N, Sato M, Houkkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Origasa H, et al. One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event Reduction after Stroke) registry. J Stroke Cerebrovasc Dis. 2012;21(4):245–53.

16. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Cockroft KM, Gutierrez J, Lombrano M, Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, Oishi Y, Imai H, et al. Ten-year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2015;86(7):776–82.

17. Fujihara K, Igarashi R, Yamamoto M, Ishizawa M, Matsubayashi Y, Matsunaga S, Kato K, Tsuchiya K, Maeda H, Nakamura H, et al. Impact of glucose
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.
39. Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, Nakamura M, Numata T, Tamakoshi A, Tsushima K. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014;8(5):e466–75.
40. Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, Fukunaga R, Bandai Y, Tajima N, Nakamura Y, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171(5):1352–60.
41. Nam KW, Kwon HM, Jeong HY, Park JH, Kwon H, Jeong SM. High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study. Cardiovasc Diabetol. 2020;19(1):53.
42. Tu WJ, Qiu HC, Liu YK, Liu Q, Zeng X, Zhao J. Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke. Cardiovasc Diabetol. 2020;19(1):1.
43. Wang Y, O’Neill A, Jiao Y, Wang L, Huang J, Lan Y, Zhu Y, Yu C. Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants. BMC Med. 2019;17:136.
44. Parizadeh D, Rahimian N, Akbarpour S, Azizi F, Hadaegh F. Sex-specific clinical outcomes of impaired glucose status: a long follow-up from the Tehran Lipid and Glucose Study. Eur J Prev Cardiol. 2019;26(10):1080–91.
45. GBD 2016 Lifetime Risk of Stroke Collaborators, Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parmar PG, Abajobir AA, Abate KH, Abd-Allah F, Abeje AE, et al. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. N Engl J Med. 2018;379(23):2429–37.
46. Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, Yamaguchi H, Ohnuma H, Tominaga M, Kato T. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample—the Funagata study. Metabolism. 2008;57(3):333–8.
47. Thacker EL, Psaty BM, McKnight B, Heckbert SR, Longstreth WT Jr, Mukamal KJ, Meigs JB, de Boer IH, Boyko EJ, Carnethon MR, et al. Fasting and post-glucose load measures of insulin resistance and risk of ischemic stroke in older adults. Stroke. 2011;42(12):3347–51.
48. Hoshino T, Uchiyama S, Wong LKS, Kitagawa K, Charles H, Labreuche J, Lavallée PC, Albers GW, Caplan LR, Donnan GA, et al. Five-year prognosis after TIA or minor ischemic stroke in Asian and non-Asian populations. Neurology. 2021;96(1):e54–66.
49. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–73.
50. Törn D, Di Angelantonio E, Di Mascio MT, Vinko R, Bath PM, PRoFESS Study Group. Types of stroke recurrence in patients with ischemic stroke: a substudy from the PRoFESS trial. Int J Stroke. 2014;9(7):573–8.
51. Kabootari M, Hasheminia M, Azizi F, Mirbolouk M, Hadaegh F. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study. Cardiovasc Diabetol. 2020;19(1):41.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions